Moleculin Biotech
MBRX
MBRX
23 hedge funds and large institutions have $5.26M invested in Moleculin Biotech in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Holders
23
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$47.3K | |
| 2 | +$25.7K | |
| 3 | +$20.5K | |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$19K |
| 5 |
Two Sigma Advisers
New York
|
+$10.3K |
Top Sellers
| 1 | -$87K | |
| 2 | -$41K | |
| 3 | -$41K | |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$37K |
| 5 |
Goldman Sachs
New York
|
-$22K |